Invent Medic Sweden (IMS) Q1 2026 earnings summary

Executive summary

• Achieved record quarterly sales and significantly improved results year-over-year.

• March marked the first month with positive cash flow, a milestone toward sustainable profitability.

• Strategic focus on existing products, key markets, and partnerships is yielding commercial and operational results.

• Transitioned to a distributor model in Sweden to accelerate market penetration and support international growth.

Financial highlights

• Net revenue for Q1 2026 was 2,059 KSEK, up from 2,000 KSEK in Q1 2025.

• Result before tax improved to -831 KSEK from -1,400 KSEK year-over-year.

• Earnings per share improved to -0.01 SEK from -0.02 SEK year-over-year.

• Total operating costs decreased to -2,836 KSEK from -3,325 KSEK year-over-year.

• Period cash flow was 127 KSEK, compared to -653 KSEK in Q1 2025.

Outlook and guidance

• Continued ambition for sustainable growth and strengthened market position in 2026.

• Focus remains on organic growth in existing business areas and increased sales in selected markets to reach break-even.